Discrete choice experiments in health economics: past, present and future
V Soekhai, EW de Bekker-Grob, AR Ellis, CM Vass - Pharmacoeconomics, 2019 - Springer
Abstract Objectives Discrete choice experiments (DCEs) are increasingly advocated as a
way to quantify preferences for health. However, increasing support does not necessarily …
way to quantify preferences for health. However, increasing support does not necessarily …
[HTML][HTML] Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force
AB Hauber, JM González, CGM Groothuis-Oudshoorn… - Value in health, 2016 - Elsevier
Conjoint analysis is a stated-preference survey method that can be used to elicit responses
that reveal preferences, priorities, and the relative importance of individual features …
that reveal preferences, priorities, and the relative importance of individual features …
Considering renal risk while managing cancer
VB Shahinian, A Bahl, D Niepel… - Cancer management and …, 2017 - Taylor & Francis
Renal function is an important consideration in the management of patients with advanced
cancer. There is a reciprocal relationship between cancer and the kidney: chronic kidney …
cancer. There is a reciprocal relationship between cancer and the kidney: chronic kidney …
Prevalence of bone metastases and bone-targeting agent use among solid tumor patients in the United States
RK Hernandez, A Adhia, SW Wade… - Clinical …, 2015 - Taylor & Francis
Purpose Patients with bone metastases are at an increased risk of experiencing morbidity
due to bone complications, and bone-targeting agents (BTA) are indicated for the prevention …
due to bone complications, and bone-targeting agents (BTA) are indicated for the prevention …
Real-world use of denosumab and bisphosphonates in patients with solid tumours and bone metastases in Germany
I Diel, S Ansorge, D Hohmann, C Giannopoulou… - Supportive Care in …, 2020 - Springer
Purpose Bisphosphonates and denosumab prevent bone complications in patients with
bone metastases from solid tumours. This retrospective, longitudinal, cohort study provides …
bone metastases from solid tumours. This retrospective, longitudinal, cohort study provides …
A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes
AB Hauber, H Nguyen, J Posner… - … medical research and …, 2016 - Taylor & Francis
Objective: Understanding patients' preferences for attributes of injectable antihyperglycemic
regimens may improve patient satisfaction and medication adherence. Our objective was to …
regimens may improve patient satisfaction and medication adherence. Our objective was to …
Examination of burden of skeletal-related events in patients naive to denosumab and intravenous bisphosphonate therapy in bone metastases from solid tumors …
D Bhowmik, X Song, M Intorcia, S Gray… - … medical research and …, 2019 - Taylor & Francis
Abstract Objectives: Skeletal-related events (SREs), ie pathologic fractures, spinal cord
compression, surgery and radiation to bone, are serious skeletal complications that occur …
compression, surgery and radiation to bone, are serious skeletal complications that occur …
Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment
FX Liu, EA Witt, S Ebbinghaus… - Patient preference …, 2017 - Taylor & Francis
Purpose To examine and compare patient and oncologist preferences for advanced
melanoma treatment attributes and to document their trade-offs for benefits with risks …
melanoma treatment attributes and to document their trade-offs for benefits with risks …
Longitudinal patterns of bone-targeted agent use among patients with solid tumors and bone metastases in the United States
Y Qian, D Bhowmik, N Kachru… - Supportive Care in Cancer, 2017 - Springer
Purpose This study examined real-world long-term use of guideline-recommended bone
targeted agents (BTA) among patients with metastatic solid tumors. Methods Adults with a …
targeted agents (BTA) among patients with metastatic solid tumors. Methods Adults with a …
Physician knowledge, practice patterns, and barriers encountered regarding guideline‐concordant use of bone modifying agents for prostate cancer
AP Mitchell, S Persaud, P Palyca, A Salner… - The …, 2024 - Wiley Online Library
Background Guidelines recommend bone‐modifying agents (BMAs) for patients with
castrate‐resistant prostate cancer (CRPC) and bone metastasis, but not for castrate …
castrate‐resistant prostate cancer (CRPC) and bone metastasis, but not for castrate …